# Glucagon: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on glucagon — the 29-amino-acid pancreatic counter-regulatory hormone. FDA-approved since 1960 for severe-hypoglycemia rescue, graded A on decades of human RCTs, and now the glucagon-receptor arm of next-generation metabolic agonists.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Glucagon is one of the most evidence-mature peptides in this program. For **emergency rescue of severe hypoglycemia** it is graded **A** — backed by human RCTs across every modern formulation (nasal Baqsimi, ready-to-use Gvoke, analog Zegalogue) plus six decades of FDA-approved use since 1960. It is also a label-approved diagnostic GI relaxant. The 2026 frontier is the **glucagon receptor as a drug target** inside dual and triple metabolic agonists.[8](https://peptidevox.com/#r8)[12](https://peptidevox.com/#r12)

Glucagon is the body's principal counter-regulatory hormone to insulin — a 29-amino-acid pancreatic alpha-cell peptide that binds the hepatic glucagon receptor to drive glucose out of the liver.[1](https://peptidevox.com/#r1) Unlike most peptides discussed in fitness and recovery circles, glucagon is not an experimental research chemical: it is an FDA-approved emergency medicine with a deep, mature human evidence base. This monograph lays out what is genuinely proven, what is mechanistically promising, and where the boundaries are.

*This article is informational and editorial content for general education only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Glucagon is a prescription-only emergency medicine, and severe hypoglycemia is a medical emergency — call 911. Dosing figures are reported strictly as seen in FDA labeling and the published literature for completeness, not as recommendations. Consult a licensed clinician and the current FDA prescribing information before any use.*

## What is glucagon and how does it work?

Glucagon is a single straight-chain polypeptide of 29 amino acids (sequence HSQGTFTSDYSKYLDSRRAQDFVQWLMNT), molecular mass approximately 3,485 Da, synthesized in the pancreatic alpha-cells of the islets of Langerhans by cleavage of proglucagon.[7](https://peptidevox.com/#r7)[3](https://peptidevox.com/#r3) Pharmaceutical glucagon is produced as recombinant human glucagon in yeast.[12](https://peptidevox.com/#r12)

Its physiologic actions are mediated by the glucagon receptor (GCGR), a class-B G-protein-coupled receptor expressed predominantly on hepatocytes. Binding activates the cascade Gsa to adenylyl cyclase to cyclic AMP to protein kinase A (PKA), with a secondary Gq to phospholipase-C arm contributing.[3](https://peptidevox.com/#r3)[5](https://peptidevox.com/#r5) PKA activation in turn activates glycogen phosphorylase and inactivates glycogen synthase, producing a net surge of glycogenolysis; the liberated glucose-6-phosphate is dephosphorylated and exported as free glucose to the blood.[4](https://peptidevox.com/#r4) In parallel, glucagon potentiates gluconeogenesis from lactate, alanine, pyruvate and glycerol. A 2020 *Nature* paper refined this, showing glucagon stimulates hepatic gluconeogenesis via INSP3R1-mediated intrahepatic lipolysis, raising hepatic acetyl-CoA and mitochondrial fat oxidation.[6](https://peptidevox.com/#r6)

Beyond glucose, GCGR activation also increases energy expenditure, promotes hepatic fat oxidation, suppresses hepatic lipogenesis, and reduces appetite via CNS pathways — the basis for its use in metabolic combination drugs.[23](https://peptidevox.com/#r23) One critical dependency governs the rescue effect: because it works through glycogenolysis, glucagon only works if sufficient hepatic glycogen is present, and it is ineffective in starvation, adrenal insufficiency or chronic hypoglycemia.[8](https://peptidevox.com/#r8) Pharmacokinetically the half-life is short — roughly 8 to 18 minutes after IV and about 35 minutes after intranasal dosing in adults — with glucose rising within 5 to 20 minutes and returning toward baseline within one to two hours.[19](https://peptidevox.com/#r19)[20](https://peptidevox.com/#r20)

## What is the evidence by indication?

Glucagon's flagship indication is graded firmly at A on the strength of randomized controlled trials and six decades of approved use. The table summarizes the evidence tier by use.

  Glucagon evidence by indication

    IndicationBest evidenceGrade

    Severe-hypoglycemia rescue (insulin-treated diabetes)Multiple device/formulation RCTs (Baqsimi, Gvoke, Zegalogue) + 60 yr of clinical useA (human RCT)
    Diagnostic GI smooth-muscle relaxantFDA label-approved; supported by procedural studiesA/B
    Glucagon-receptor arm of dual/triple metabolic agonistsPhase 2/3 RCTs of survodutide & retatrutide (combination molecules)A (for the combination)
    Beta-blocker / calcium-channel-blocker overdoseMechanistic + case-series + guideline (off-label)C/D

For the flagship indication, the trial record is consistent. Nasal glucagon (Baqsimi 3 mg) was FDA-approved on July 24, 2019 — the first and only nasally administered glucagon — and in pediatric trials all participants achieved a glucose increase of at least 20 mg/dL within 30 minutes, with comparable efficacy to injectable glucagon in adults.[10](https://peptidevox.com/#r10)[8](https://peptidevox.com/#r8) The ready-to-use liquid Gvoke was validated across multiple Phase 3 insulin-induced-hypoglycemia studies.[14](https://peptidevox.com/#r14)[15](https://peptidevox.com/#r15) Dasiglucagon (Zegalogue), a glucagon analog, was approved on three randomized, double-blind, placebo-controlled Phase 3 trials, with median glucose recovery of 10 minutes versus 30 to 45 minutes for placebo and 99% of adults recovering within 15 minutes.[16](https://peptidevox.com/#r16)[18](https://peptidevox.com/#r18) The full pediatric Phase 3 dasiglucagon RCT is indexed on PubMed Central at [PMC8361970](https://pmc.ncbi.nlm.nih.gov/articles/PMC8361970/) for readers who want the primary data.[18](https://peptidevox.com/#r18)

Proven vs hyped
Proven: severe-hypoglycemia rescue and diagnostic GI relaxation. Not proven: glucagon as a standalone weight-loss or performance drug — that framing is unsupported. The real metabolic story is the glucagon *receptor* as a target inside combination agonists, not glucagon monotherapy for weight.[21](https://peptidevox.com/#r21)

## What is the 2026 metabolic-agonist frontier?

The renewed scientific importance of glucagon in 2026 is as the glucagon-receptor arm of next-generation incretin agonists. The therapeutic logic: GLP-1 suppresses appetite and improves glycemia, but adding controlled glucagon-receptor agonism layers on hepatic fat oxidation, reduced lipogenesis and increased energy expenditure.[23](https://peptidevox.com/#r23)

Survodutide (BI 456906), a GLP-1/glucagon dual agonist, delivered striking Phase 2 results in metabolic dysfunction-associated steatohepatitis: in the 48-week NEJM trial (n=295), up to 83.0% of survodutide patients achieved histologic MASH improvement without worsening fibrosis versus 18.2% on placebo, and up to 52% showed fibrosis improvement — the first GLP-1/glucagon dual agonist to show this fibrosis benefit.[21](https://peptidevox.com/#r21)[22](https://peptidevox.com/#r22) Its Phase 3 obesity program reports roughly 16.6% mean weight loss.[24](https://peptidevox.com/#r24) Retatrutide (LY3437943), a GIP/GLP-1/glucagon triple agonist, showed up to 24.2% mean weight loss at 48 weeks in Phase 2; a meta-analysis of three RCTs (n=878) found pooled weight reduction of −14.33% versus placebo and HbA1c reduction of −0.91%.[26](https://peptidevox.com/#r26)[27](https://peptidevox.com/#r27) In 2026 the Phase 3 TRIUMPH-1 obesity trial met its primary endpoints and TRANSCEND-T2D-1 showed significant HbA1c and weight reductions.[25](https://peptidevox.com/#r25)[28](https://peptidevox.com/#r28)

From a functional-medicine standpoint, these agents validate a root-cause insight: hepatic and energy-expenditure biology — the glucagon axis — not appetite alone, drives metabolic disease. The glucagon-receptor component directly targets liver fat and thermogenesis rather than masking symptoms, which is why dual and triple agonism outperforms GLP-1 monotherapy on MASH and weight endpoints. This is graded on the combination-molecule RCTs, not on glucagon monotherapy for weight, which is neither approved nor proven on its own.

## What doses appear in the literature?

Reported strictly as information from FDA labeling and trials, not a protocol. For severe-hypoglycemia rescue, reconstituted GlucaGen or generic glucagon is 1 mg (0.5 mg for small children) by IM, SC or IV — reconstitute with 1 mL sterile water, inject immediately, and discard the unused portion.[12](https://peptidevox.com/#r12)[13](https://peptidevox.com/#r13) Gvoke ready-to-use liquid is 1 mg/0.2 mL SC for adults and 0.5 mg/0.1 mL for children, with no reconstitution.[15](https://peptidevox.com/#r15) Baqsimi nasal powder is a single 3 mg actuation into one nostril that does not need to be inhaled; if there is no response after 15 minutes, a second device and emergency services are indicated.[8](https://peptidevox.com/#r8) Dasiglucagon (Zegalogue) is a 0.6 mg SC single dose.[17](https://peptidevox.com/#r17) For the diagnostic GI indication, 0.2 to 0.5 mg IV or 1 mg IM relaxes the stomach and small bowel.[12](https://peptidevox.com/#r12) The newer ready-to-use products eliminate reconstitution and are designed for lay-caregiver use under stress.

## How safe is glucagon, and what is its legal status?

The most common adverse events are nausea, vomiting and headache; the nasal product additionally causes upper-respiratory and ocular irritation.[8](https://peptidevox.com/#r8)[12](https://peptidevox.com/#r12) Glucagon can raise blood pressure and heart rate and increase myocardial oxygen demand, so cardiac monitoring is advised in diagnostic use in patients with heart disease.[12](https://peptidevox.com/#r12) Hypokalemia can occur, and rebound hypoglycemia is possible as the effect wanes within one to two hours.[12](https://peptidevox.com/#r12) Rare hypersensitivity, including anaphylactic shock, has been reported.[8](https://peptidevox.com/#r8) It is contraindicated in pheochromocytoma (catecholamine release), insulinoma (rebound hypoglycemia) and known hypersensitivity, and is ineffective in glycogen-depleted states.[8](https://peptidevox.com/#r8)[12](https://peptidevox.com/#r12) Because it is a short-acting natural hormone, not an angiogenic growth-factor peptide, the tumor-angiogenesis concerns raised for some research peptides do not apply to acute rescue use.

Legally, glucagon is an FDA-approved drug, not a research chemical — approved since 1960, prescription-only, and not a DEA-controlled substance.[8](https://peptidevox.com/#r8)[12](https://peptidevox.com/#r12) It is dispensed as a commercial product (GlucaGen, Gvoke, Baqsimi, Zegalogue) rather than compounded from bulk peptide, and the "research-chemical, not-for-human-use" framing does not apply.[16](https://peptidevox.com/#r16) The combination agonists retatrutide and survodutide remain investigational in 2026.[25](https://peptidevox.com/#r25) For athletes, glucagon is not on the 2025 WADA Prohibited List, with no major status changes; related GLP-1 incretins are monitored, not banned, and athletes should verify current status at GlobalDRO.com.[29](https://peptidevox.com/#r29)[30](https://peptidevox.com/#r30)

**Bottom line.** Glucagon pairs decades of high-quality human evidence with FDA approval since 1960. For severe-hypoglycemia rescue and diagnostic GI relaxation the indications are genuinely proven and graded A; it is not a standalone weight-loss or performance drug. The real 2026 story is the glucagon receptor as a drug target inside survodutide and retatrutide, where the key open questions are the long-term safety and durability of chronic glucagon-receptor agonism and the final regulatory outcomes — neither combination agonist is FDA-approved yet. Rescue glucagon remains a prescription emergency medicine; severe hypoglycemia is a 911 emergency, and this document is educational, not medical advice.

---
Source: https://peptidevox.com/peptide-encyclopedia/glucagon
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt